References

Parkinson’s disease

10.1016/s0140-6736(21)00218-x · 2021 · External reference

Diagnosis and treatment of Parkinson disease: A review

10.1001/jama.2019.22360 · 2020 · External reference

Parkinson disease

10.1038/nrdp.2017.13 · 2017 · External reference

The Parkinson pandemic-A call to action

10.1001/jamaneurol.2017.3299 · 2018 · External reference

Parkinson’s disease

10.1016/s0140-6736(14)61393-3 · 2015 · External reference

The peripheral blood transcriptome dynamically reflects system wide biology: A potential diagnostic tool

10.1016/j.lab.2005.10.005 · 2006 · External reference

Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood

10.1038/s41467-018-04558-1 · 2018 · External reference

Circulating blood circular RNA in Parkinson’s disease; from involvement in pathology to diagnostic tools in at-risk individuals

2024 · External reference

10.1101/2024.10.18.24315717

10.1101/2024.10.18.24315717 · External reference

A review of genome-wide transcriptomics studies in Parkinson’s disease

10.1111/ejn.13760 · 2018 · External reference

RNA sequencing of whole blood reveals early alterations in immune cells and gene expression in Parkinson’s disease

10.1038/s43587-021-00088-6 · 2021 · External reference

Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-genome wide association study

10.1016/s1474-4422(19)30320-5 · 2019 · External reference

Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson’s disease

10.1038/s41467-023-39652-6 · 2023 · External reference

Multi-modality machine learning predicting Parkinson’s disease

2022 · External reference

Assessment of heterogeneity among participants in the Parkinson’s progression markers initiative cohort using α-synuclein seed amplification: A cross-sectional study

10.1016/s1474-4422(23)00109-6 · 2023 · External reference

β-synuclein regulates the phase transitions and amyloid conversion of α-synuclein

10.1038/s41467-024-53086-8 · 2024 · External reference

Parkinson’s disease biomarkers program brain imaging repository

10.1016/j.neuroimage.2015.05.005 · 2016 · External reference

The Parkinson progression marker initiative (PPMI)

10.1016/j.pneurobio.2011.09.005 · 2011 · External reference

The BioFIND study: Characteristics of a clinically typical Parkinson’s disease biomarker cohort

10.1002/mds.26613 · 2016 · External reference

Genetic and multi-omic resources for Alzheimer disease and related dementia from the Knight Alzheimer Disease Research Center

10.1038/s41597-024-03485-9 · 2024 · External reference

Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression

10.1038/s41531-024-00636-y · 2024 · External reference

Parkinson’s disease in women and men: What’s the difference?

2019 · External reference

Global trends in the incidence, prevalence, and years lived with disability of Parkinson’s disease in 204 countries/territories from 1990 to 2019

10.3389/fpubh.2021.776847 · 2021 · External reference

The NINDS Parkinson’s disease biomarkers program

10.1002/mds.26438 · 2016 · External reference

Parkinson’s disease biomarkers: Perspective from the NINDS Parkinson’s disease biomarkers program

10.2217/bmm-2016-0370 · 2017 · External reference

STAR: Ultrafast universal RNA-seq aligner

10.1093/bioinformatics/bts635 · 2013 · External reference

Unresolved reference

External reference

Salmon provides fast and bias-aware quantification of transcript expression

10.1038/nmeth.4197 · 2017 · External reference

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

10.1186/s13059-014-0550-8 · 2014 · External reference

RNA-seq: Impact of RNA degradation on transcript quantification

10.1186/1741-7007-12-42 · 2014 · External reference

Immunedeconv: An R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data

10.1007/978-1-0716-0327-7_16 · 2020 · External reference

Differential meta-analysis of RNA-seq data from multiple studies

10.1186/1471-2105-15-91 · 2014 · External reference

clusterProfiler: An R package for comparing biological themes among gene clusters

10.1089/omi.2011.0118 · 2012 · External reference

DOSE: An R/bioconductor package for disease ontology semantic and enrichment analysis

10.1093/bioinformatics/btu684 · 2015 · External reference

multiGSEA: A GSEA-based pathway enrichment analysis for multi-omics data

10.1186/s12859-020-03910-x · 2020 · External reference

Imai K. Mediation: R package for causal mediation analysis

10.18637/jss.v059.i05 · 2014 · External reference

Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease

10.1038/s41588-023-01584-8 · 2024 · External reference

Common X-chromosome variants are associated with Parkinson disease risk

10.1002/ana.26051 · 2021 · External reference

The Parkinson’s disease genome-wide association study locus browser

10.1002/mds.28197 · 2020 · External reference

BEDTools: A flexible suite of utilities for comparing genomic features

10.1093/bioinformatics/btq033 · 2010 · External reference

Second-generation PLINK: Rising to the challenge of larger and richer datasets

10.1186/s13742-015-0047-8 · 2015 · External reference

Cell-free RNA signatures predict Alzheimer’s disease

10.1016/j.isci.2023.108534 · 2023 · External reference

Unresolved reference

External reference

Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: A meta-analysis of genome-wide association studies

10.1016/s1474-4422(19)30320-5 · 2019 · External reference

Molecular markers of early Parkinson’s disease based on gene expression in blood

10.1073/pnas.0610204104 · 2007 · External reference

Evaluation of RNA blood biomarkers in the Parkinson’s disease biomarkers program

10.3389/fnagi.2018.00157 · 2018 · External reference

Identification of potential blood biomarkers for Parkinson’s disease by gene expression and DNA methylation data integration analysis

10.1186/s13148-019-0621-5 · 2019 · External reference

Analysis of blood-based gene expression in idiopathic Parkinson disease

10.1212/wnl.0000000000004516 · 2017 · External reference

Nucleo-cytoplasmic transport defects and protein aggregates in neurodegeneration

10.1186/s40035-020-00205-2 · 2020 · External reference

RNA nucleocytoplasmic transport defects in neurodegenerative diseases

10.1007/978-3-319-89689-2_4 · 2018 · External reference

The mechanistic role of alpha-synuclein in the nucleus: Impaired nuclear function caused by familial Parkinson’s disease SNCA mutations

10.1093/hmg/ddaa183 · 2020 · External reference

Enhanced serum-based seed amplification assay for detecting propagative α-synuclein seeds in Parkinson’s disease

10.1186/s40035-025-00488-3 · 2025 · External reference

Alpha-synuclein seeding amplification assays in Lewy body dementia: A brief review

10.1186/s13024-025-00868-3 · 2025 · External reference

Neuropathologic validation and diagnostic accuracy of presynaptic dopaminergic imaging in the diagnosis of parkinsonism

10.1212/wnl.0000000000209453 · 2024 · External reference

Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism

10.1186/s13550-023-01025-x · 2023 · External reference

STAT3 protects dopaminergic neurons against degeneration in animal model of Parkinson’s disease

10.1016/j.brainres.2023.148691 · 2024 · External reference

Exome sequencing and the identification of new genes and shared mechanisms in polymicrogyria

10.1001/jamaneurol.2023.2363 · 2023 · External reference

Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans

10.1073/pnas.0901931106 · 2009 · External reference

Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast

10.1002/j.1460-2075.1989.tb03615.x · 1989 · External reference

Identification and characterization of the human ARD1-NATH protein acetyltransferase complex

10.1042/bj20041071 · 2005 · External reference

Interaction of N-terminal acetyltransferase with the cytoplasmic domain of beta-amyloid precursor protein and its effect on A beta secretion

10.1093/jb/mvi014 · 2005 · External reference

Loss of amino-terminal acetylation suppresses a prion phenotype by modulating global protein folding

10.1038/ncomms5383 · 2014 · External reference

Amyloid-associated activity contributes to the severity and toxicity of a prion phenotype

10.1038/ncomms5384 · 2014 · External reference

Chaperone protein HYPK interacts with the first 17 amino acid region of huntingtin and modulates mutant HTT-mediated aggregation and cytotoxicity

10.1016/j.bbrc.2014.11.035 · 2015 · External reference

Defining the limits: Protein aggregation and toxicity in vivo

10.3109/10409238.2014.914151 · 2014 · External reference

HYPK, a Huntingtin interacting protein, reduces aggregates and apoptosis induced by N-terminal Huntingtin with 40 glutamines in Neuro2a cells and exhibits chaperone-like activity

10.1093/hmg/ddm301 · 2008 · External reference

Praja1 ubiquitin ligase facilitates degradation of polyglutamine proteins and suppresses polyglutamine-mediated toxicity

10.1091/mbc.e20-11-0747 · 2021 · External reference

Praja1 RING-finger E3 ubiquitin ligase is a common suppressor of neurodegenerative disease-associated protein aggregation

10.1111/neup.12840 · 2022 · External reference

Molecular signatures of neuroinflammation induced by αSynuclein aggregates in microglial cells

10.3389/fimmu.2020.00033 · 2020 · External reference

Association between circulating protein C levels and incident dementia: The atherosclerosis risk in communities study

10.1159/000516287 · 2021 · External reference

Cellular glutathione peroxidase in human brain: Cellular distribution, and its potential role in the degradation of Lewy bodies in Parkinson’s disease and dementia with Lewy bodies

10.1007/s00401-008-0438-3 · 2009 · External reference

Glutathione peroxidase 4 is associated with neuromelanin in substantia Nigra and dystrophic axons in Putamen of Parkinson’s brain

10.1186/1750-1326-6-8 · 2011 · External reference

Changes in selenoprotein P in substantia Nigra and Putamen in Parkinson’s disease

2012 · External reference

Blood-brain barrier leakage is increased in Parkinson’s disease

10.3389/fphys.2020.593026 · 2020 · External reference

Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson’s disease model

10.1016/j.brainres.2018.09.036 · 2019 · External reference

PPARs and their neuroprotective effects in Parkinson’s disease: A novel therapeutic approach in α-synucleinopathy?

10.3390/ijms24043264 · 2023 · External reference

Dysregulation of mitochondrial and proteolysosomal genes in Parkinson’s disease myeloid cells

10.1038/s43587-021-00110-x · 2021 · External reference

Exercise training upregulates CD55 to suppress complement-mediated synaptic phagocytosis in Parkinson’s disease

10.1186/s12974-024-03234-0 · 2024 · External reference

Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease

10.1186/s13041-019-0436-5 · 2019 · External reference

Microglia mediate forgetting via complement-dependent synaptic elimination

10.1126/science.aaz2288 · 2020 · External reference

Inactivation of BRD7 results in impaired cognitive behavior and reduced synaptic plasticity of the medial prefrontal cortex

10.1016/j.bbr.2015.02.031 · 2015 · External reference

BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-кB signaling pathway

10.1038/cmi.2016.31 · 2017 · External reference

Nucleoporin Seh1 interacts with Olig2/Brd7 to promote oligodendrocyte differentiation and myelination

10.1016/j.neuron.2019.02.018 · 2019 · External reference

Identification of potential immune-related hub genes in Parkinson’s disease based on machine learning and development and validation of a diagnostic classification model

10.1371/journal.pone.0294984 · 2023 · External reference

Suppression of a core metabolic enzyme dihydrolipoamide dehydrogenase (dld) protects against amyloid beta toxicity in C. elegans model of Alzheimer’s disease

10.1016/j.gendis.2020.08.004 · 2021 · External reference

Testing for linkage and association across the dihydrolipoyl dehydrogenase gene region with Alzheimer’s disease in three sample populations

10.1007/s11064-006-9235-3 · 2007 · External reference

Reduced activities of thiamine-dependent enzymes in the brains and peripheral tissues of patients with Alzheimer’s disease

10.1001/archneur.1988.00520320022009 · 1988 · External reference

Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain

10.1002/ana.410130116 · 1983 · External reference

An immunohistochemical study on alpha-ketoglutarate dehydrogenase complex in Parkinson’s disease

10.1002/ana.410350212 · 1994 · External reference

Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson’s disease

10.1007/bf02260943 · 1994 · External reference

Novel functions of the alpha-ketoglutarate dehydrogenase complex may mediate diverse oxidant-induced changes in mitochondrial enzymes associated with Alzheimer’s disease

10.1016/j.bbadis.2007.12.008 · 2008 · External reference

Deficits in the mitochondrial enzyme α-ketoglutarate dehydrogenase lead to Alzheimer’s disease-like calcium dysregulation

10.1016/j.neurobiolaging.2011.11.003 · 2012 · External reference